Developer docs
API playgroundTry for free, no card

Search company profiles

Micreos

Full company profile

uuid000223b

Namestring
Micreos
Legal namestring
Micreos Pharmaceuticals AG
Websiteurl
micreos.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Micreos is a Swiss-headquartered biotech platform developing engineered endolysin and phage-based antimicrobials that selectively kill specific pathogenic bacteria while preserving the surrounding microbiome. Founded in 2005 in the Netherlands and now organized around Micreos Pharmaceuticals AG (incorporated in Baar, Switzerland) with drug discovery and pre-clinical operations in Zurich and Bilthoven, the company operates three distinct business units: (1) a clinical-stage pharmaceutical pipeline led by MEndoB (a first-in-class dual-acting molecular domain endolysin targeting Staphylococcus aureus in Atopic Dermatitis, with planned Phase I/IIa entry in late 2026) alongside XZ.700, SP.800, and MEndoC; (2) the Gladskin over-the-counter skincare brand selling endolysin-based products to consumers with acne, eczema, and rosacea across Europe and the USA; and (3) the PhageGuard food safety business providing FDA- and USDA-approved phage products against Listeria, Salmonella, and E. coli to meat, poultry, fish, cheese, and produce processors.

The underlying technology was developed in collaboration with ETH Zurich and exploits the peptidoglycan-hydrolyzing activity of bacteriophage-derived enzymes (endolysins) as precision antimicrobials. Pre-clinical data highlight high specificity for S. aureus (including MRSA), activity against biofilms and at the low pH of diseased atopic skin, and no observed resistance emergence after repeated sub-lethal exposure. The pharmaceutical unit monetizes through future licensing and commercialization of approved biologics; Gladskin generates transactional revenue through e-commerce and retail pharmacy; PhageGuard sells B2B through direct enterprise sales to food processors. Distribution spans Switzerland, the Netherlands, the USA, Germany, France, and the UK, with CDMO scale-up for MEndoB handled by Northway Biotech under a March 2025 strategic partnership. The pharmaceutical business was spun out as an independent company in March 2023 to access capital markets directly, and the firm has raised approximately €57 million in disclosed venture funding across 2021 and 2022 alone, with cumulative disclosed capital exceeding €80 million including earlier rounds and EU grants.

Short descriptiontext

Micreos is a Swiss biotech platform developing engineered endolysin and phage-based antimicrobials that selectively kill harmful bacteria while preserving the microbiome, operating three units: clinical-stage pharmaceuticals (lead MEndoB for Atopic Dermatitis), the Gladskin OTC skincare brand, and the PhageGuard food safety business.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBilthoven, Netherlands
HQ citystring
Bilthoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered endolysin technology, targeted antimicrobial therapeutics, skin microbiome treatments, phage-based food safety, biological antibacterial platform
Industry1 code
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Food And Kindred Products2000
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Programs
TypeOne Time License
Description

Clinical development of endolysin-based therapeutics targeting bacteria including MRSA for bloodstream infections, atopic dermatitis, diabetic foot ulcers, and cutaneous T-cell lymphoma. Revenue anticipated from future drug approvals and commercialization.

micreos.com
2Gladskin OTC Skincare
TypeTransaction Fee
Description

Over-the-counter skincare products for inflammatory skin conditions (acne, eczema, rosacea) caused by S. aureus. Products sold in Europe and USA with hundreds of thousands of customers. Revenue from product sales through e-commerce and retail channels.

micreos.com
3PhageGuard Food Safety
TypeTransaction Fee
Description

FDA and USDA-approved phage products against food pathogens (Listeria, Salmonella, E. coli) for food processing companies in meat, poultry, fish, cheese, and fresh produce industries.

micreos.com
4Technology Licensing
TypeLicensing Royalties
Description

Partnership opportunities for designing, testing, and manufacturing precision antimicrobials through Antimicrobial Protein and Antimicrobial Vector platforms.

micreos.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1OTC Skincare Products - Gladskin
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Gladskin brand products for inflammatory skin conditions available for purchase through e-commerce and retail channels. Specific pricing not publicly disclosed in source materials.

micreos.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Gladskin
Description

Specialized skincare brand for people suffering from inflammatory skin conditions such as acne, eczema, and rosacea caused or aggravated by Staphylococcus aureus. OTC products helping hundreds of thousands of people in Europe and USA.

micreos.com
+1 more record
Core offering1 text field

Micreos is a platform biotechnology company developing engineered endolysin-based therapeutics and products for the targeted elimination of harmful bacteria while preserving the beneficial microbiome. The company operates three integrated business units: clinical-stage pharmaceutical programs (lead molecule MEndoB targeting Staphylococcus aureus in Atopic Dermatitis), over-the-counter skincare products under the Gladskin brand for inflammatory skin conditions, and PhageGuard FDA/USDA-approved phage-based food safety products for food processing industries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • S. aureus present in up to 90% of Atopic Dermatitis patients
+5 more records
Product overview1 text field

Micreos is a platform biotech company built around its proprietary engineered endolysin technology that enables targeted killing of only unwanted bacteria while preserving the rest of the microbiome. The company operates across three business segments: (1) Pharmaceuticals - developing clinical-stage therapeutics including lead candidate MEndoB and XZ.700 for dermatology (Atopic Dermatitis), oncology (Cutaneous T-cell Lymphoma), and bloodstream infections; (2) Consumer Health - Gladskin OTC brand for inflammatory skin conditions; (3) Food Safety - PhageGuard products for food pathogen control. The platform technology has been developed in collaboration with ETH Zurich and represents a sustainable alternative to traditional antibiotics with no expected drug resistance.

Product and service2 records
1Gladskin
CategoryConsumer Health Skincare
2PhageGuard
CategoryFood Safety
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-04
Description

Strategic partnership with Contract Development and Manufacturing Organization (CDMO) Northway Biotech to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB. Partnership includes developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation. Northway Biotech headquartered in Vilnius, Lithuania with locations in London, UK and Waltham, MA, USA.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-02-06
Description

Collaboration with Prof. Steffi Lehmann from ZHAW on MEndoB research demonstrating successful eradication of staphylococcal infections in zebrafish and mouse models.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-02-06
Description

Collaboration with Prof. Dr. med. Annelies Zinkernagel from University Hospital Zurich on MEndoB research published in mBio journal.

4University of Copenhagen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-07
Description

Research collaboration with University of Copenhagen's Skin Immunology Research Centre led by Prof. Niels Ødum. Study published in Journal of Investigative Dermatology demonstrating endolysin XZ.700 effectiveness in CTCL treatment. Ground-breaking data on S. aureus and drug resistance in malignant T-cells published in Blood journal in January 2024.

micreos.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-22
Description

Medical and technology centre collaboration for endolysin research and development.

6Academic Centre for Dentistry Amsterdam (ACTA)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-22
Description

Academic partnership for dental/oral health applications of endolysin technology.

micreos.com
7Public Health Lab Kennemerland
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-22
Description

Partnership with public health laboratory for microbiological research and validation.

micreos.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2005-01-01
Description

Long-standing collaboration with pre-eminent University ETH Zurich for endolysin technology development. Professor Martin Loessner from ETH Zurich is co-author on XZ.700 research. Dr. Matthew Dunne, Dr. Samuel Kilcher, and Dr. Anja Keller joined from ETH Zurich to build Antimicrobial Vector Engineering team.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage US biotech developing lysin-based therapeutics (exebacase) for serious bacterial infections including Staphylococcus aureus bacteremia. Most direct endolysin therapeutic peer; similar modality, MRSA focus, and clinical-stage positioning.

TypeDirect peer
Description

Engineered phage and endolysin platform company developing precision antimicrobials targeting specific bacterial pathogens, including S. aureus and other AMR pathogens. Closely comparable modality (engineered phage-derived proteins) and clinical-stage focus.

TypeDirect peer
Description

French biotech developing engineered phage-based antimicrobials ("eligobiotics") that selectively kill specific bacteria while preserving the microbiome. Mirrors Micreos' precision-killing, microbiome-preserving thesis with parallel technology approach.

TypeDirect peer
Description

Clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections including S. aureus. Comparable precision antibacterial approach for AMR indications though focused on phage rather than endolysins.

TypeDirect peer
Description

Swiss clinical-stage antibacterial company developing small-molecule therapeutics to overcome antimicrobial resistance, with hospital-acquired infection programs. Comparable European biotech addressing AMR crisis with clinical-stage pipeline.

TypeDirect peer
Description

US-based phage technology company with FDA-approved phage products (ListShield, SalmoFresh, EcoShield) for food safety applications against Listeria, Salmonella, and E. coli. Direct competitor to Micreos' PhageGuard food safety division.

7Phagelux
TypeDirect peer
Description

China/US phage biotech developing phage-based products for food safety (Listeria, Salmonella) and human therapeutic applications. Comparable dual food-safety and therapeutic phage strategy overlapping with both Micreos' PhageGuard and pharma units.

TypeEmerging player
Description

Late-stage specialty pharma developing anti-infective and adjunctive therapies including Mino-Lok (catheter lock solution) and treatments targeting antibiotic-resistant infections. Adjacent AMR focus with later-stage clinical assets.

TypeBroad incumbent
Description

Large pharmaceutical company with Regeneron-partnered Dupixent (dupilumab), the market-leading biologic for Atopic Dermatitis. Sets the efficacy/reimbursement benchmark MEndoB must compete against in AD and represents a potential large-pharma partner or acquirer.

TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with broad portfolio across acne, rosacea, eczema, and skin microbiome products. Comparable consumer-dermatology presence to Gladskin and potential commercialization partner for Micreos' endolysin assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micreos

Biopharmaceuticalsmicreos.com

Micreos is a Swiss biotech platform developing engineered endolysin and phage-based antimicrobials that selectively kill harmful bacteria while preserving the microbiome, operating three units: clinical-stage pharmaceuticals (lead MEndoB for Atopic Dermatitis), the Gladskin OTC skincare brand, and the PhageGuard food safety business.

What Micreos does

Micreos is a Swiss-headquartered biotech platform developing engineered endolysin and phage-based antimicrobials that selectively kill specific pathogenic bacteria while preserving the surrounding microbiome. Founded in 2005 in the Netherlands and now organized around Micreos Pharmaceuticals AG (incorporated in Baar, Switzerland) with drug discovery and pre-clinical operations in Zurich and Bilthoven, the company operates three distinct business units: (1) a clinical-stage pharmaceutical pipeline led by MEndoB (a first-in-class dual-acting molecular domain endolysin targeting Staphylococcus aureus in Atopic Dermatitis, with planned Phase I/IIa entry in late 2026) alongside XZ.700, SP.800, and MEndoC; (2) the Gladskin over-the-counter skincare brand selling endolysin-based products to consumers with acne, eczema, and rosacea across Europe and the USA; and (3) the PhageGuard food safety business providing FDA- and USDA-approved phage products against Listeria, Salmonella, and E. coli to meat, poultry, fish, cheese, and produce processors.

The underlying technology was developed in collaboration with ETH Zurich and exploits the peptidoglycan-hydrolyzing activity of bacteriophage-derived enzymes (endolysins) as precision antimicrobials. Pre-clinical data highlight high specificity for S. aureus (including MRSA), activity against biofilms and at the low pH of diseased atopic skin, and no observed resistance emergence after repeated sub-lethal exposure. The pharmaceutical unit monetizes through future licensing and commercialization of approved biologics; Gladskin generates transactional revenue through e-commerce and retail pharmacy; PhageGuard sells B2B through direct enterprise sales to food processors. Distribution spans Switzerland, the Netherlands, the USA, Germany, France, and the UK, with CDMO scale-up for MEndoB handled by Northway Biotech under a March 2025 strategic partnership. The pharmaceutical business was spun out as an independent company in March 2023 to access capital markets directly, and the firm has raised approximately €57 million in disclosed venture funding across 2021 and 2022 alone, with cumulative disclosed capital exceeding €80 million including earlier rounds and EU grants.

Micreos firmographics

Firmographics
Name
Micreos
Legal name
Micreos Pharmaceuticals AG
Website
https://micreos.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Micreos is a Swiss biotech platform developing engineered endolysin and phage-based antimicrobials that selectively kill harmful bacteria while preserving the microbiome, operating three units: clinical-stage pharmaceuticals (lead MEndoB for Atopic Dermatitis), the Gladskin OTC skincare brand, and the PhageGuard food safety business.
Ownership category
akta.pro rank

Micreos industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Food And Kindred Products (2000), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)

Keywords

  • Engineered endolysin technology
  • Targeted antimicrobial therapeutics
  • Skin microbiome treatments
  • Phage-based food safety
  • Biological antibacterial platform

Where Micreos is headquartered

Location

Headquarters

HQ city
Bilthoven
HQ country
Netherlands
HQ region
Europe

Offices6 records

Markets served

Micreos business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Programs: Clinical development of endolysin-based therapeutics targeting bacteria including MRSA for bloodstream infections, atopic dermatitis, diabetic foot ulcers, and cutaneous T-cell lymphoma. Revenue anticipated from future drug approvals and commercialization.
  2. Gladskin OTC Skincare: Over-the-counter skincare products for inflammatory skin conditions (acne, eczema, rosacea) caused by S. aureus. Products sold in Europe and USA with hundreds of thousands of customers. Revenue from product sales through e-commerce and retail channels.
  3. PhageGuard Food Safety: FDA and USDA-approved phage products against food pathogens (Listeria, Salmonella, E. coli) for food processing companies in meat, poultry, fish, cheese, and fresh produce industries.
  4. Technology Licensing: Partnership opportunities for designing, testing, and manufacturing precision antimicrobials through Antimicrobial Protein and Antimicrobial Vector platforms.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goOTC Skincare Products - Gladskin

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Micreos product offering

Product offering

Core offering

Micreos is a platform biotechnology company developing engineered endolysin-based therapeutics and products for the targeted elimination of harmful bacteria while preserving the beneficial microbiome. The company operates three integrated business units: clinical-stage pharmaceutical programs (lead molecule MEndoB targeting Staphylococcus aureus in Atopic Dermatitis), over-the-counter skincare products under the Gladskin brand for inflammatory skin conditions, and PhageGuard FDA/USDA-approved phage-based food safety products for food processing industries.

Product overview

Micreos is a platform biotech company built around its proprietary engineered endolysin technology that enables targeted killing of only unwanted bacteria while preserving the rest of the microbiome. The company operates across three business segments: (1) Pharmaceuticals - developing clinical-stage therapeutics including lead candidate MEndoB and XZ.700 for dermatology (Atopic Dermatitis), oncology (Cutaneous T-cell Lymphoma), and bloodstream infections; (2) Consumer Health - Gladskin OTC brand for inflammatory skin conditions; (3) Food Safety - PhageGuard products for food pathogen control. The platform technology has been developed in collaboration with ETH Zurich and represents a sustainable alternative to traditional antibiotics with no expected drug resistance.

Differentiator

Problem solved

Functional benefit

Brands

  • Gladskin: Specialized skincare brand for people suffering from inflammatory skin conditions such as acne, eczema, and rosacea caused or aggravated by Staphylococcus aureus. OTC products helping hundreds of thousands of people in Europe and USA.
  • Phageguard

Products and services

  • Gladskin
  • PhageGuard

Quantifiable outcome

  • S. aureus present in up to 90% of Atopic Dermatitis patients
  • +5 more outcomes

Companies that use Micreos

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Micreos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Micreos partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Northway BiotechcoreStrategic or Co-development Partner · 4 March 2025Strategic partnership with Contract Development and Manufacturing Organization (CDMO) Northway Biotech to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB. Partnership includes developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation. Northway Biotech headquartered in Vilnius, Lithuania with locations in London, UK and Waltham, MA, USA.
  • Zurich University of Applied Sciences (ZHAW)minorStrategic or Co-development Partner · 6 February 2024Collaboration with Prof. Steffi Lehmann from ZHAW on MEndoB research demonstrating successful eradication of staphylococcal infections in zebrafish and mouse models.
  • University Hospital ZurichminorStrategic or Co-development Partner · 6 February 2024Collaboration with Prof. Dr. med. Annelies Zinkernagel from University Hospital Zurich on MEndoB research published in mBio journal.
  • University of CopenhagencoreStrategic or Co-development Partner · 7 March 2023Research collaboration with University of Copenhagen's Skin Immunology Research Centre led by Prof. Niels Ødum. Study published in Journal of Investigative Dermatology demonstrating endolysin XZ.700 effectiveness in CTCL treatment. Ground-breaking data on S. aureus and drug resistance in malignant T-cells published in Blood journal in January 2024.
  • Erasmus Medical Centre RotterdamminorStrategic or Co-development Partner · 22 September 2020Medical and technology centre collaboration for endolysin research and development.
  • Academic Centre for Dentistry Amsterdam (ACTA)minorStrategic or Co-development Partner · 22 September 2020Academic partnership for dental/oral health applications of endolysin technology.
  • Public Health Lab KennemerlandminorStrategic or Co-development Partner · 22 September 2020Partnership with public health laboratory for microbiological research and validation.
  • ETH Zurich (Swiss Federal Institute of Technology)coreStrategic or Co-development Partner · 1 January 2005Long-standing collaboration with pre-eminent University ETH Zurich for endolysin technology development. Professor Martin Loessner from ETH Zurich is co-author on XZ.700 research. Dr. Matthew Dunne, Dr. Samuel Kilcher, and Dr. Anja Keller joined from ETH Zurich to build Antimicrobial Vector Engineering team.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Micreos competitors and assessment

Company assessment

Direct peers

  • ContraFect Corporation: Clinical-stage US biotech developing lysin-based therapeutics (exebacase) for serious bacterial infections including Staphylococcus aureus bacteremia. Most direct endolysin therapeutic peer; similar modality, MRSA focus, and clinical-stage positioning.
  • Locus Biosciences: Engineered phage and endolysin platform company developing precision antimicrobials targeting specific bacterial pathogens, including S. aureus and other AMR pathogens. Closely comparable modality (engineered phage-derived proteins) and clinical-stage focus.
  • Eligo Bioscience: French biotech developing engineered phage-based antimicrobials ("eligobiotics") that selectively kill specific bacteria while preserving the microbiome. Mirrors Micreos' precision-killing, microbiome-preserving thesis with parallel technology approach.
  • Adaptive Phage Therapeutics: Clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections including S. aureus. Comparable precision antibacterial approach for AMR indications though focused on phage rather than endolysins.
  • BioVersys AG: Swiss clinical-stage antibacterial company developing small-molecule therapeutics to overcome antimicrobial resistance, with hospital-acquired infection programs. Comparable European biotech addressing AMR crisis with clinical-stage pipeline.
  • Intralytix: US-based phage technology company with FDA-approved phage products (ListShield, SalmoFresh, EcoShield) for food safety applications against Listeria, Salmonella, and E. coli. Direct competitor to Micreos' PhageGuard food safety division.
  • Phagelux: China/US phage biotech developing phage-based products for food safety (Listeria, Salmonella) and human therapeutic applications. Comparable dual food-safety and therapeutic phage strategy overlapping with both Micreos' PhageGuard and pharma units.

Emerging players

  • Citius Pharmaceuticals: Late-stage specialty pharma developing anti-infective and adjunctive therapies including Mino-Lok (catheter lock solution) and treatments targeting antibiotic-resistant infections. Adjacent AMR focus with later-stage clinical assets.

Broad incumbents

  • Sanofi (Dupixent): Large pharmaceutical company with Regeneron-partnered Dupixent (dupilumab), the market-leading biologic for Atopic Dermatitis. Sets the efficacy/reimbursement benchmark MEndoB must compete against in AD and represents a potential large-pharma partner or acquirer.
  • Galderma: Global dermatology-focused pharmaceutical company with broad portfolio across acne, rosacea, eczema, and skin microbiome products. Comparable consumer-dermatology presence to Gladskin and potential commercialization partner for Micreos' endolysin assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Micreos social profiles

Digital presence

Micreos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micreos leadership team

Management profile

Number of profiles

Profiles8 records

Micreos subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Micreos funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micreos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micreos

What does Micreos do?

Micreos is a platform biotechnology company developing engineered endolysin-based therapeutics and products for the targeted elimination of harmful bacteria while preserving the beneficial microbiome. The company operates three integrated business units: clinical-stage pharmaceutical programs (lead molecule MEndoB targeting Staphylococcus aureus in Atopic Dermatitis), over-the-counter skincare products under the Gladskin brand for inflammatory skin conditions, and PhageGuard FDA/USDA-approved phage-based food safety products for food processing industries.

Is Micreos a public or private company?

Micreos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Micreos founded?

Micreos was founded in 2005. It employs 11 to 50 people.

Where is Micreos based?

Micreos is headquartered in Bilthoven, Netherlands, in the Europe region.

How does Micreos make money?

Four revenue lines are on record. Pharmaceutical Programs are the primary driver. The others are gladskin OTC Skincare, phageGuard Food Safety and technology Licensing.

Who are Micreos's main competitors?

Direct peers on record are ContraFect Corporation, Locus Biosciences, Eligo Bioscience, Adaptive Phage Therapeutics, BioVersys AG, Intralytix and Phagelux. Citius Pharmaceuticals is listed as an emerging player. Broad incumbents are Sanofi (Dupixent) and Galderma.

Does Micreos have an API?

No public API is recorded for Micreos.

What industry is Micreos in?

Micreos's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cosmetics BusinessL’Oréal makes ‘groundbreaking’ link-up with Micreos to develop microbiome-targeted skin careL'Oréal entered a licensing deal with Dutch biotech Micreos to access its endolysin protein for microbiome-targeted skincare. The protein targets unwanted skin bacteria while sparing beneficial ones. L'Oréal has published over 50 papers on the skin microbiome since 2006.MorningstarMicreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing ProgramMicreos Pharmaceuticals partnered with Northway Biotech to develop scalable cGMP production for its engineered endolysin MEndoB, targeting atopic dermatitis. Northway will provide cGMP drug substance by the end of summer 2024, supporting clinical trials.Business InsiderMicreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing ProgramMicreos Pharmaceuticals partnered with Northway Biotech to develop scalable cGMP production for its engineered endolysin MEndoB, targeting atopic dermatitis. Northway will provide cGMP drug substance by the end of summer 2024, supporting clinical trials.PR NewswireUne étude expérimentale met en évidence que l'endolysine recombinante XZ.700* est une nouvelle stratégie de traitement non antibiotique prometteuse visant à contrôler la colonisation de la peau lésionMicreos announced positive results from an experimental study led by the University of Copenhagen demonstrating that its recombinant endolysin XZ.700 inhibits Staphylococcus aureus colonization and malignant T cell activation in cutaneous T cell lymphoma (CTCL). The findings suggest this non-antibiotic treatment could offer a viable alternative to antibiotics, which are prone to inducing resistance, thereby addressing significant unmet medical needs for CTCL patients. Consequently, Micreos is advancing its research and development program towards the next-generation endolysin MEndoC.PR NewswireLa endolisina XZ.700* controla la colonización por S. aureus de la piel en el linfoma cutáneo de células TMicreos announced positive preclinical research results demonstrating that its endolysin XZ.700 inhibits Staphylococcus aureus colonization and malignant T-cell activation in cutaneous T-cell lymphoma (CTCL). Based on these findings, the company is advancing its development program from XZ.700 to a next-generation endolysin, MEndoC, which exhibits higher intrinsic activity. This strategic shift aims to address antimicrobial resistance concerns and provide a non-antibiotic treatment option for CTCL patients.PR NewswireDie Studie zeigt, dass rekombinantes Endolysin XZ.700* eine erfolgversprechende nicht-antibiotische Behandlung zur Kontrolle der Besiedlung von Hautläsionen mit Staphylococcus aureus (S. aureus) bei kResearch led by Prof. Niels Ødum at the University of Copenhagen's Research Center for Skin Immunology found that Micreos' recombinant endolysin XZ.700* effectively inhibits Staphylococcus aureus colonization on both healthy skin and CTCL-affected skin lesions, while also killing S. aureus after colonization was already established. The study, published in the Journal of Infectious Disease 2023, showed that XZ.700* may block the tumor-promoting effects of S. aureus on malignant T-cells, potentially delaying disease progression in cutaneous T-cell lymphoma. Based on these encouraging preclinical results, Micreos has advanced its CTCL development program from XZ.700* to the next-generation endolysin MEndoC, which demonstrates higher intrinsic activity.PR NewswireInvestigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization ofMicreos reported positive pre-clinical results from a study led by the University of Copenhagen showing that its investigational endolysin XZ.700 inhibits Staphylococcus aureus colonization and malignant T cell activation in cutaneous T-cell lymphoma (CTCL). The findings suggest the treatment could delay tumor progression and address unmet medical needs, prompting Micreos to advance its research program toward the next-generation endolysin MEndoC.PR NewswireInvestigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization ofMicreos reported positive results from an investigational study showing that its recombinant endolysin XZ.700 inhibits Staphylococcus aureus colonization and blocks tumor-promoting effects in patients with cutaneous T-cell lymphoma (CTCL). The findings support the strategic shift of Micreos' development program from XZ.700 to a next-generation endolysin, MEndoC, which exhibits higher intrinsic activity levels for clinical trials.FinSMEsMicreos Secures €25M in Growth FundingDutch/Swiss biotech company Micreos raised €25 million in undisclosed growth funding, led by CEO Mark Offerhaus, to fund its skincare brand Gladskin and its pharmaceutical program. Proceeds support clinical development of endolysin treatments for staphylococci, including MRSA, in bloodstream infections, atopic dermatitis, diabetic foot ulcers and cutaneous T-cell lymphoma.BioSpaceMicreos’ Alternative to Antibiotics Secures Next €25 MillionDutch/Swiss biotech company Micreos announced it has raised €25 million in growth capital and for clinical development of its endolysin technology platform, which targets only unwanted bacteria. Proceeds fund the skincare brand Gladskin and the pharmaceutical program, including endolysins against staphylococci for bloodstream infections, atopic dermatitis, diabetic foot ulcers and cutaneous T-cell lymphoma.